TOKYO, July 22, 2020 ―CMIC HOLDINGS Co., Ltd.(Head Office: Tokyo, Minato-ku, Representative Director & CEO Kazuo Nakamura, hereafter “CMIC”)announced today the establishment of CMIC BIO Co., Ltd. (hereafter CMIC BIO), a fully-owned subsidiary that offers Contract Development and Manufacturing Organization (hereinafter CDMO) services for biopharmaceutical drug substance. CMIC Bio has a single-use facility in Shizuoka, Japan for process development and GMP manufacturing of antibody drug using mammalian cell line. The facility will be in full-scale operation from October 2020.

In recent years, the biopharmaceutical-related market has continued to expand, and companies from other industries other than pharmaceutical companies have entered the market. Each company emphasizes the speed to acquire POC in order to quickly identify the development compound, and at the same time, the need for multi-product, small-volume production is rising. Given this situation, it is difficult to produce all of the development products in-house, and an increasing number of cases utilize outsourcing.

For the period from April 2014 to September 2019, CMIC JSR Biologics Co., Ltd. participated in the Japan Science and Technology Agency’s Program (NexTEP) (Project name: design and  manufacturing technology of multispecific antibodies). Research has been conducted in the fields of manufacturing and quality control of biotechnology-derived pharmaceuticals, with a focus on the manufacturing process development of bispecific antibodies. Based on these experiences, we establish CMIC Bio and start the biopharmaceutical drug substances CDMO business.” At CMIC Bio, we have personnel with abundant experience at pharmaceutical companies and have strengths in GMP API manufacturing bases in Japan to assist in accelerating the development speed of biopharmaceuticals.” Commented Hiroshi Kosaku, President of CMIC Pharmaceutical Sciences.
“CMIC Group will provide end to end solutions from non-clinical testing, running clinical trial, GMP manufacturing of biopharmaceuticals to the commercialization and post market.”

■Summary of CMIC BIO

(1) Trade nameCMIC Bio Co., Ltd.
(2) Head Office1-1, Shibaura 1-chome, Minato-ku, Tokyo
(3) Facilities588 Higashi 1-chome, Kanaya, Shimada, Shizuoka (Shizuoka Plant of CMIC CMO Co.,Ltd.)
(4) RepresentativeRepresentative Director, Kosaku Hiroshi
(5) Business Description
  • Contract manufacturing of antibody drug substances
  • Support activities for biopharmaceutical R&D
  • Support work for the development of materials and materials related to biopharmaceutical manufacturing
  • Consulting activities related to biopharmaceutical R&D
(6) Capital Gold300 million yen
(7) Date of establishmentMay 1, 2020
(8) Number of employees11

 

■About CMIC Group
CMIC Group was founded in 1992 as the first Contract Research Organization (CRO) in Japan. Today CMIC Group is the largest clinical CRO in Japan with global footprint, providing comprehensive services in drug development, clinical site management, clinical to commercial GMP manufacturing, regulatory consulting and contract sales & marketing solutions. We can help pharmaceutical, biotech and medical device companies to enter Japan market, to conduct clinical trials in Asia, or to bridge drug development and manufacturing needs in the US, Europe, Japan and broader Asia. CMIC Group has over 7,000 employees and 25 sites globally.

【Contact us】
[Media Contact]
PR Group, CMIC HOLDINGS CO., LTD.
E-mail: pr@cmic.co.jp

[Sales Contact Information]
CMIC Bio Co., Ltd.
Phone:+81-547-46-4956
E-mail: yoshimi-murata.sg@cmic.co.jp